OCT-A has become a major trend in the development of OCT in recent years.
Optical coherence tomography (OCT) is a high-resolution, non-contact, non-invasive biological tissue imaging technology that can perform real-time, high-resolution microstructures in multiple tissues of the human body. Imaging, especially suitable for ophthalmic examination and other optical detection fields, is called “optical biopsy” and is also regarded as the “gold standard” in the field of ophthalmic diagnosis.
OCT angiography (OCT-A) is a new application of OCT technology. Compared with traditional OCT, OCT-A not only analyzes the intensity of reflected signals, but also analyzes the time-varying reflection information caused by the movement of moving substances such as red blood cells in blood vessels, thereby real-time imaging of blood vessels Morphology and blood flow), which can be applied to the diagnosis of ophthalmic diseases, dermatological diseases and cardiovascular diseases; in addition, OCT-A also displays a series of two-dimensional cross sections in any orientation Image, Three-dimensional data image obtained after layered scanning (En-face) is of great significance for disease diagnosis.
As a result, OCT-A has become a major trend in the development of OCT in recent years. From the perspective of clinical application, the traditional diagnosis of most diseases in ophthalmology requires the use of fluorescein fundus angiography (FFA) and OCT. Although FFA is effective in diagnosing retinal disease, it is easy to cause patients to have some adverse reactions during the examination, such as nausea, dizziness, allergies, and even life-threatening. OCT-A technology also provides an effective alternative.
OCT-A shows a large number of new blood vessels in the retina
The probe capital organize data Display Combined with the number of domestic medical institutions and market penetration rate, it is estimated that by 2022, the market capacity of major OCT-A equipment in China’s ophthalmology will approach 17 billion yuan. Many companies have started related technology research and development, and recently learned Zhenhong Technology is one of them.
Zhenhong Technology was established in 2016. It is a high-tech medical device company focusing on the R & D, production and sales of OCT and other optical imaging equipment technologies. It has a 1,000 square meter laboratory in Foshan and more than 1,000 in Tianjin. Square meter laboratory and production workshop. Not long ago, Zhenhong Technology completed a new round of financing of tens of millions of yuan , The investor is Tongchuang Weiye, and Probe Capital serves as the exclusive financial consultant .
It is reported that Zhenghong Technology currently has functions such as ophthalmic OCT technology, endoscopic OCT technology, microangiography OCT technology, and polarization-sensitive OCT technology. > Core products OCT, glaucoma elastic microcatheters and other products have independent intellectual property rights and core manufacturing processes. In addition, Zhenghong Technology is also developing products including anterior segment OCT-A, surgical OCT-A, and children’s handheld OCT-A.
Among them, Ophthalmic OCT-A system is the core product, and will get an NMPA certificate. Before obtaining the NMPA registration certificate, its ophthalmic OCT-A was mainly marketed as a scientific research product. The product can add polarization-sensitive, phase-sensitive, and elastic imaging functions according to user needs. It is reported that At present, Zhenghong Technology has established scientific research cooperation relationship with Beijing Tongren Hospital, PLA General Hospital and other top ophthalmology hospitals.
Anlin, the founder of Zhenghong Technology, revealed that compared with the one million yuan OCT-A products of Zeiss and Heidelberg in Germany, the price of Zhenghong Technology’s OCT-A is only three points one.
In the field of OCT technology, there are many well-known companies participating. Zeiss (Carl Zeiss), OPTOVUE, TOPCON, Heidelberg, etc. are the representatives, and they are also markets in this field. Four largest share. In comparison, although China’s ophthalmic OCT equipment has made great technological breakthroughs after many years of development, the industry’s technical level still has a certain gap compared with foreign countries. At present, price competition is mainly in the domestic market. For example, in the case of OCT-A, only Zhenghong Technology currently owns OCT-A-related independent intellectual property rights and core manufacturing processes.
In terms of team, An Lin, co-founder of Zhenghong Technology, graduated from the Department of Bioengineering of the University of Washington in the United States. He has developed the world’s first OCTA film as a core R & D staff of Zeiss OCT-A. In addition, Zhenghong Technology’s engineering team also gathered a group of talents with technical foundations in the fields of optics, software algorithms, medical catheter technology, and precision mechanical design.